廣生堂(300436.SZ):廣生中霖與上海藥明康德簽訂3CL蛋白酶抑制劑合作開發合同書
格隆匯12月24日丨廣生堂(300436.SZ)公佈,2021年12月23日,公司召開第四屆董事會第九次會議,審議通過了《關於控股子公司廣生中霖與上海藥明康德簽訂抗新型冠狀病毒小分子口服藥3CL蛋白酶抑制劑合作開發合同書的議案》,同意公司控股子公司福建廣生中霖生物科技有限公司(作為甲方)與上海藥明康德新藥開發有限公司(作為乙方)就用於新冠病毒感染治療的一類新藥研發項目口服小分子3-CL(3C-like)蛋白酶抑制劑簽訂《合作開發合同書》。
2021年12月24日,雙方簽署了《合作開發合同書》。該次開發合同的簽訂將進一步豐富公司在抗病毒藥物領域的佈局,打造優質的創新藥產品管線,為中國及全球抗疫貢獻力量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.